In a study of 13 myelofibrosis patients, 45% of 11 evaluable patients had a more than 10% spleen reduction. Credit: Gorodenkoff / Shutterstock.com.
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer.
The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people.
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
In a clinical study involving 13 patients with myelofibrosis (median age 68 years), who had failed a median of two therapies previously, 45% of 11 evaluable patients achieved more than 10% spleen volume reduction.
Symptom burden was reduced by more than 50% in 78% of nine evaluable patients. All three evaluable patients showed improvement in transfusion burden.
These results were presented at the 67th Annual Meeting of the American Society of Hematology in December 2025.
GlobalData Strategic Intelligence
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
Learn more about Strategic Intelligence
At a median 195-day follow-up, ten patients were alive; two changed therapy class, three underwent stem cell transplant, and others continued initial ruxolitinib treatment.
Responders showed reduced plasma and bone marrow monocytes, decreased inflammatory cytokines (TGFβ1, TGFβ2, FGF, PDGF, sCD40L), and normalisation of bone marrow myeloid to erythroid ratio.
Cellenkos’ founder Dr Simrit Parmar said: “Receiving orphan drug designation is an important milestone in the clinical development of CK0804 for myelofibrosis and underscores our commitment to advance CK0804 into Phase II trials to address the unmet need for patients who have not responded to currently available therapies.
“The observed increase in IL-10 and decreases in TGFβ levels in CK0804 responders, together with reductions in pathogenic monocytes in plasma and bone marrow, support the disease-modifying potential of CK0804 Tregs as a distinct and differentiated therapeutic class in myelofibrosis.”
In April 2024, Cellenkos
signed a sponsored research agreement
with the Icahn School of Medicine at Mount Sinai Hospital, New York, US, to investigate the use of CK0804 for myelofibrosis.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva
.
Editorial content is independently produced and follows the
highest standards
of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free eBook
Navigating cell therapy process development
The cell therapy manufacturing sector is rapidly evolving, driven by the need to balance innovative process development with rigorous GMP standards. This eBook, brought to you by industry leaders Cytiva, explores how biotech firms can address common challenges — including minimizing contamination risks from manual processes, overcoming resource limitations, and creating scalable, robust designs. Industry experts discuss strategies including automation, strategic outsourcing, and flexible equipment selection to streamline processes and reduce regulatory risks. To unlock expert insights on optimizing your cell therapy pathway from clinical development to commercialization, fill in your details now.
Thank you.
You will receive an email shortly. Please check your inbox to download the eBook.
By Cytiva Thematic
You have a right to withdraw your consent at any time, by
clicking here
. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our
privacy policy
.
Pharmaceutical Technology Excellence Awards - Nominations Closed
Nominations are now closed for the
Pharmaceutical Technology Excellence Awards
. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in
Integrated Manufacturing
, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.
Discover the Impact
